​

Corbus Pharmaceuticals (CRBP) Stock Forecast, Price Target & Predictions

OverviewFinancialsChart

CRBP Stock Forecast

Corbus Pharmaceuticals (CRBP) stock forecast, based on 13 Wall Street analysts, predicts a 12-month average price target of $47.50, with a high of $60.00 and a low of $35.00. This represents a 687.73% increase from the last price of $6.03.

$5 $17 $29 $41 $53 $65 High: $60 Avg: $47.5 Low: $35 Last Closed Price: $6.03

CRBP Stock Rating

Corbus Pharmaceuticals stock's rating consensus is Buy, based on 13 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 11 Buy (84.62%), 2 Hold (15.38%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 13 0 2 11 Strong Sell Sell Hold Buy Strong Buy

CRBP Price Target Upside V Benchmarks

TypeNameUpside
StockCorbus Pharmaceuticals687.73%
SectorHealthcare Stocks 35.94%
IndustryBiotech Stocks 83.61%

Price Target Trends

1M3M12M
# Anlaysts--9
Avg Price Target--$68.44
Last Closing Price$6.03$6.03$6.03
Upside/Downside--1034.99%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 2537---10
Mar, 2537---10
Feb, 2536---9
Jan, 2536---9
Dec, 2436---9
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 02, 2024Biren AminPiper Sandler$35.00$17.8296.41%480.43%
Oct 21, 2024Jeff JonesOppenheimer$60.00$18.41225.91%895.02%
Sep 20, 2024Kalpit PatelB.Riley Financial$40.00$19.51105.02%563.35%
Sep 13, 2024Graig SuvannavejhMizuho Securities$74.00$51.5843.47%1127.20%
Aug 07, 2024Jeff JonesOppenheimer$88.00$48.3082.19%1359.37%
Jul 22, 2024Andres MaldonadoH.C. Wainwright$80.00$58.0037.93%1226.70%
Jun 11, 2024Brian AbrahamsRBC Capital$82.00$43.8786.92%1259.87%
Jun 03, 2024Jeff JonesOppenheimer$80.00$42.8086.92%1226.70%
May 20, 2024Brian AbrahamsRBC Capital$77.00$45.0071.11%1176.95%
Mar 06, 2024Maury RaycroftJefferies$46.00$33.5836.99%662.85%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Dec 02, 2024Piper SandlerOverweightinitialise
Oct 21, 2024OppenheimerOutperformOutperformhold
Sep 23, 2024OppenheimerBuyBuyhold
Sep 23, 2024H.C. WainwrightBuyBuyhold
Sep 20, 2024WedbushOutperformOutperformhold
Sep 20, 2024B. RileyBuyBuyhold
Sep 20, 2024OppenheimerOutperformOutperformhold
Aug 07, 2024OppenheimerOutperformOutperformhold
Jul 29, 2024WedbushOutperforminitialise
Jun 25, 2024B. RileyBuyinitialise

Financial Forecast

EPS Forecast

$-50 $-40 $-30 $-20 $-10 $0 Dec 20 Dec 21 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-42.74$-11.11$-10.31$-3.68----
Avg Forecast$-48.18$-12.38$-10.66$-4.31$-5.66$-5.47$-6.37$-6.16
High Forecast$-48.18$-12.38$-10.52$-4.03$-3.02$-3.13$-3.33$-6.16
Low Forecast$-48.18$-12.38$-10.79$-4.62$-12.23$-7.75$-9.62$-6.16
Surprise %-11.29%-10.26%-3.28%-14.62%----

Revenue Forecast

$0 $8M $16M $24M $32M $40M Dec 20 Dec 21 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$3.94M$881.71K------
Avg Forecast$4.77M$1.12M-$9.98M$2.00M$7.40M$6.76M$35.29M
High Forecast$4.77M$1.12M-$9.98M$2.00M$7.40M$6.76M$35.29M
Low Forecast$4.77M$1.12M-$9.98M$2.00M$7.40M$6.76M$35.29M
Surprise %-17.52%-21.23%------

Net Income Forecast

$-250M $-200M $-150M $-100M $-50M $0 Dec 20 Dec 21 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-111.30M$-45.55M$-44.60M$-40.21M----
Avg Forecast$-208.50M$-53.55M$-46.11M$-18.72M$-33.00M$-23.54M$-28.03M$-26.66M
High Forecast$-208.50M$-53.55M$-45.52M$-17.46M$-13.08M$-13.52M$-14.41M$-26.66M
Low Forecast$-208.50M$-53.55M$-46.70M$-19.97M$-52.92M$-33.55M$-41.65M$-26.66M
Surprise %-46.62%-14.94%-3.27%114.82%----

CRBP Forecast FAQ

Is Corbus Pharmaceuticals stock a buy?

Corbus Pharmaceuticals stock has a consensus rating of Buy, based on 13 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 11 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Corbus Pharmaceuticals is a favorable investment for most analysts.

What is Corbus Pharmaceuticals's price target?

Corbus Pharmaceuticals's price target, set by 13 Wall Street analysts, averages $47.5 over the next 12 months. The price target range spans from $35 at the low end to $60 at the high end, suggesting a potential 687.73% change from the previous closing price of $6.03.

How does Corbus Pharmaceuticals stock forecast compare to its benchmarks?

Corbus Pharmaceuticals's stock forecast shows a 687.73% upside, outperforming the average forecast for the healthcare stocks sector (35.94%) and outperforming the biotech stocks industry (83.61%).

What is the breakdown of analyst ratings for Corbus Pharmaceuticals over the past three months?

  • April 2025: 30.00% Strong Buy, 70.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 30.00% Strong Buy, 70.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 33.33% Strong Buy, 66.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Corbus Pharmaceuticals’s EPS forecast?

Corbus Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2025 is $-5.66, marking a 53.80% increase from the reported $-3.68 in 2024. Estimates for the following years are $-5.47 in 2026, $-6.37 in 2027, and $-6.16 in 2028.

What is Corbus Pharmaceuticals’s revenue forecast?

Corbus Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2025 is $2M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $7.4M, followed by $6.76M for 2027, and $35.29M for 2028.

What is Corbus Pharmaceuticals’s net income forecast?

Corbus Pharmaceuticals's net income forecast for the fiscal year ending in December 2025 stands at $-33.003M, representing a -17.92% decrease from the reported $-40.209M in 2024. Projections indicate $-23.536M in 2026, $-28.029M in 2027, and $-26.658M in 2028.